CD40 ligation prevents onset of tolerogenic properties in human dendritic cells treated with CTLA-4-Ig.
The synthetic immunomodulator cytotoxic T lymphocyte antigen 4-Ig (CTLA-4-Ig) initiates effects in human monocyte-derived dendritic cells (DC) that rely on immunosuppressive tryptophan catabolism. However, it is unable to induce suppressive properties in DC matured by CD40 engagement. Thus, CD40-driven events may physiologically set human DC free from restraint by regulatory cells expressing surface CTLA-4.
Vacca
Carmine
C
Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Italy.
Fallarino
Francesca
F
Perruccio
Katia
K
Orabona
Ciriana
C
Bianchi
Roberta
R
Gizzi
Stefania
S
Velardi
Andrea
A
Fioretti
Maria Cristina
MC
Puccetti
Paolo
P
Grohmann
Ursula
U
D000069594:Abatacept; D000818:Animals; D019013:CD40 Antigens / Q000502:physiology*; D049109:Cell Proliferation; D003713:Dendritic Cells / Q000187:drug effects* / Q000502:physiology*; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects*; D018796:Immunoconjugates / Q000494:pharmacology*; D007371:Interferon-gamma / Q000502:physiology; D051379:Mice; D008811:Mice, Inbred DBA; D011485:Protein Binding; D014364:Tryptophan / Q000378:metabolism; D014366:Tryptophan Oxygenase / Q000378:metabolism; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
D019013:CD40 Antigens; D018796:Immunoconjugates; D000069594:Abatacept; D007371:Interferon-gamma; D014364:Tryptophan; D014366:Tryptophan Oxygenase; D048051:p38 Mitogen-Activated Protein Kinases